TG Therapeutics Hits 14-Year Net Income High

Tg Therapeutics reported fiscal 2026 Q2 earnings on August 6, 2026, demonstrating a complex financial picture characterized by significant revenue growth juxtaposed with a sharp contraction in earnings per share. While the top line expanded substantially, driven by strong product sales, the bottom line saw a notable percentage decline in EPS and net income compared to the previous year. However, the absolute net income figure achieved represents a significant milestone, marking the highest quarterly net income for the company in over a decade, signaling robust operational profitability despite the diluted per-share metrics.

Revenue

Total revenue for Tg Therapeutics experienced a substantial 70.3% increase, reaching $240.34 million in the second quarter of 2026, a marked improvement from the $141.15 million recorded in the same period of 2025. This growth was primarily fueled by core business operations, with product revenue, net, contributing the bulk of the total at $235.79 million. Additionally, the company generated $4.54 million from license, milestone, royalty, and other revenue streams, culminating in the reported total revenue of $240.34 million.

Earnings/Net Income

Tg Therapeutics's EPS declined 73.7% to $0.05 in 2026 Q2 from $0.19 in 2025 Q2. Meanwhile, the company's net income declined to $7.78 million in 2026 Q2, down 72.4% from $28.19 million reported in 2025 Q2. Remarkably, in 2026 Q2, the company set a new record high for fiscal Q2 net income, the highest in 14 years. The significant drop in EPS and net income percentage is attributed to base-year comparisons or share structure changes, yet the absolute profitability remains historically strong.

Price Action

The stock price of Tg Therapeutics has climbed 3.44% during the latest trading day, has dropped 6.73% during the most recent full trading week, and has tumbled 10.08% month-to-date.

Post-Earnings Price Action Review

The stock exhibited mixed momentum in the immediate aftermath of the earnings release, reflecting investor caution despite the positive revenue trajectory. Over the most recent full trading week, the shares experienced a decline of 6.73%, indicating some profit-taking or reassessment of valuation metrics following the reported figures. However, this downward pressure was partially offset by a 3.44% gain on the latest trading day, suggesting a potential stabilization or short-term bullish sentiment. Despite the recent daily recovery, the stock remains under pressure on a broader timeframe, having tumbled 10.08% month-to-date. This volatility highlights the market's nuanced reaction to the conflicting signals of strong top-line growth versus declining per-share earnings, as investors weigh the company's historical profitability records against immediate earnings quality.

CEO Commentary

CEO of Tg Therapeutics highlighted robust business performance driven by strong revenue generation, explicitly noting that the company achieved $240.3 million in revenue and a net income of $7.8 million for the period, resulting in an EPS of $0.05. Strategic priorities centered on capitalizing on these financial successes to reinforce market positioning and sustain growth momentum. The leadership outlook conveyed a cautious optimism, emphasizing the importance of maintaining operational efficiency while navigating the evolving therapeutic landscape. By focusing on key growth drivers and addressing potential challenges through disciplined execution, the CEO underscored a commitment to long-term value creation. The tone remained balanced, acknowledging both the achievements in profitability and the need for continued strategic investments to support future expansion and competitive advantage in the biopharmaceutical sector.

Guidance

The company provided specific quantitative targets for the reported period, confirming an EPS of $0.0500 and total revenue of $240,335,000.00, with a net income of $7,781,000.00. These figures serve as the baseline for forward-looking expectations, indicating a focus on maintaining profitability and revenue stability. Qualitative expectations emphasize the continuation of current strategic initiatives aimed at optimizing operational performance and enhancing market presence. The guidance reflects a commitment to delivering consistent financial results while prioritizing sustainable growth. No specific future revenue or EPS projections were detailed beyond the confirmed official figures, suggesting a conservative approach to future outlooks. Investors are advised to monitor subsequent communications for any updates on CAPEX or additional financial metrics that may arise from ongoing strategic evaluations.

Additional News

TG Therapeutics recently announced the initiation of a Phase 2 clinical trial for BRIUMVI® (ublituximab-xiiy) targeting adults with treatment-resistant schizophrenia, marking a significant expansion of the drug's potential indications beyond its established use in autoimmune disorders. This open-label, single-arm study aims to enroll approximately 60 participants aged 18 to 60 who have not responded adequately to standard antipsychotic treatments. The trial will primarily assess efficacy through reductions in PANSS total scores after 12 weeks, alongside safety and tolerability metrics. Additionally, the company shared positive topline Phase 1 data for BRIUMVI in myasthenia gravis patients and announced plans to present new real-world data on the therapy for relapsing multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers annual meeting. These developments underscore TG Therapeutics' strategic diversification into neuropsychiatric markets while reinforcing its position in neurology.